Posts

Showing posts from September, 2017

Reverent for Dr. Asima Chatterjee !!!

Image
Dear All, Today if you get to see the  Google Doodle  it shows the deep tribute to Dr. Asima Chatterjee by creating an interesting sculptured as: Fig Source: Forbes Let’s find out why Dr. Asima Chatterjee is still in memory on her 100’s Birthday.. Many of us aware with  Bengal Chemicals & Pharmaceuticals Ltd  the  first Indian  Company to manufacture quality Chemicals, Drugs, Pharmaceuticals and Home Products, employing  indigenous technology , skill and raw materials. It was the time when  Patent and other intellectual properties  were governed by  Patents and Designs Act 1911  and ambiguities and deficiencies in that Act which were fully exploited by the foreign owned pharmaceutical companies called Trans National Corporations (TNCs). Unichem  for  tolbutamide (Sulphonamide Derivative)  had been successfully sued in Bombay High Court by   Hoe...
Image
Malaysia Issues Compulsory License for Gilead’s Sofosbuvir Despite Licence A much cheaper version of a groundbreaking hepatitis C medicine is now accessible for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir.. The decision comes right after the Gilead Sciences decided to expand its voluntary licensing scheme to Ukraine, Belarus, Malaysia, Thailand and Philippines & announce on professional platform as follows: According to the Malaysian AIDS Council  it is 500,000 people or 2.5 per cent of the general population are estimated to be living with hepatitis C in Malaysia & the cost of the full hepatitis C treatment comes to RM 300,000 per patient (US$71,300), leading to very few patients benefitting from it. Since Sofosbuvir is patented, a government-use licence is needed to waive the monopoly right and enable the sale of generic drugs. Thus, the government decision is the key to opening the...

Canada Edges Toward Patent Term Extension, CETA: Comes with New hope

Image
Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union—is moving Canada closer toward a patent term extension. On  October 31, 2016 a amended bill was introduced in   Canada parliament.  Foreign ownership and investments,  Access to public procurement contracts,  Automobiles,  Food (e.g. beef and dairy products)  Agriculture. Pharmaceuticals were also a part of the discussion. Key Facts: The supplementary protection certificate (SPC) is a right that extends the legal duration of a pharmaceutical patent for the period corresponding to that necessary to obtain marketing authorisation, requiring a long and complex administrative procedure to protect human health. Eligibility for extension:  To be eligible for patent term extension, a patent must claim: the medicinal ingredient or combination of all the medicinal ingredients contained in the drug (i.e., a "product" claim); the m...